S1 Episode 5: Transplant Tips, Talks, and Timing for Myelofibrosis

Join Drs Tania Jain and Jeanne Palmer as they discuss their approach to transplant in myelofibrosis.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999597. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Myelofibrosis and Survival Prognostic Models: A Journey Between Past and Future https://pubmed.ncbi.nlm.nih.gov/36983189/

DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status https://pubmed.ncbi.nlm.nih.gov/21149668/

Survival Following Allogeneic Transplant in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/32384540/

Posttransplant Cyclophosphamide vs Tacrolimus-based GVHD Prophylaxis: Lower Incidence of Relapse and Chronic GVHD https://pubmed.ncbi.nlm.nih.gov/37156098/

A Prognostic Model to Predict Survival After 6 Months of Ruxolitinib in Patients With Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35130339/

Advances in Pharmacotherapy for Myelofibrosis: What Is the Current State of Play? https://pubmed.ncbi.nlm.nih.gov/38738513/

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/38201581/

Superior Outcomes With Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - A Comparative Analysis by CIBMTR https://ashpublications.org/blood/article/138/Supplement%201/912/482649/Superior-Outcomes-with-Fludarabine-Busulfan-Flu-Bu

Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis With Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/35158092/

Anti-T-Lymphocyte Globulin Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis After Matched Related or Unrelated Donor Transplantation https://pubmed.ncbi.nlm.nih.gov/38773281/

Donor Types and Outcomes of Transplantation in Myelofibrosis: A CIBMTR Study https://pubmed.ncbi.nlm.nih.gov/38916866/

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis https://pubmed.ncbi.nlm.nih.gov/31288096/